cis-myrtanyl bromide | 30248-36-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: cis-myrtanyl bromide
• 英文别名: 2-(Bromomethyl)-6,6-dimethylbicyclo[3.1.1]heptane
• CAS: 30248-36-3；119027-20-2；133774-91-1
• 化学式: C₁₀H₁₇Br
• 分子量: 217.149
• InChiKey: QVRWOONDLVMOND-UHFFFAOYSA-N

物化性质

• 沸点：
  100 °C(Press: 8 Torr)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  Beta-pinene 在 硼烷 、 溴 、 sodium methylate 作用下， 生成 cis-myrtanyl bromide
  参考文献：
  名称：

  用于合成的有机硼烷。10. 1碱诱导的溴与有机硼烷的反应。通过氢硼化将烯烃转化为烷基溴的简便方法

  摘要：

  DOI：

  10.1016/s0040-4020(88)90012-9

文献信息

• Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
  申请人：Den Hartog A.J. Jacobus

  公开号：US20050075355A1

  公开（公告）日：2005-04-07

  The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description

  该发明涉及一组取代苯并咪唑酮和喹唑酮衍生物，它们是人类ORL1（nociceptin）受体上的激动剂。该发明还涉及制备这些化合物，含有至少一种这些新型苯并咪唑酮和喹唑酮衍生物的药理活性量作为活性成分的药物组合物，以及利用这些药物组合物治疗涉及ORL1受体的疾病。该发明涉及一般式（1）的化合物，其中符号的含义如描述中所给出。
• BICYCL 3.1.1]HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1670457A1

  公开（公告）日：2006-06-21
• US7851630B2
  申请人：——

  公开号：US7851630B2

  公开（公告）日：2010-12-14
• [EN] BICYCLO`3.1.1!HEPTANE SUBSTITUTED BENZIMIDAZOLONE AND QUINAZOLINONE DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS<br/>[FR] DERIVES DE LA BENZIMIDAZOLONE ET DE LA QUINAZOLINONE A SUBSTITUTION BICYCLO`3.1.1!HEPTANE, AGONISTES DU RECEPTEUR ORL1 HUMAIN
  申请人：SOLVAY PHARM BV

  公开号：WO2005032547A1

  公开（公告）日：2005-04-14

  The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1) wherein the symbols have the meanings as given in the description.